相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFR(L858R/T790M) cells to reversible EGFR tyrosine kinase inhibitors
Paola Orlandi et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data
Gianfranco Natale et al.
CANCER LETTERS (2018)
Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer
Jesus Anampa et al.
CLINICAL BREAST CANCER (2018)
Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer
Amy E. Chang et al.
CLINICAL BREAST CANCER (2018)
Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation
Mozaffar Aznab et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer
Yumun Jeong et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant,recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial
C. Dinkic et al.
GYNECOLOGIC ONCOLOGY (2017)
Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer
V. M. Patil et al.
INDIAN JOURNAL OF CANCER (2017)
Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer
Benjamin S. Jones et al.
LUNG CANCER (2017)
Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer
V. M. Patil et al.
INDIAN JOURNAL OF CANCER (2017)
Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience
Marwa Mahmoud Hussein et al.
CLINICAL BREAST CANCER (2017)
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial
Emilia Montagna et al.
CANCER LETTERS (2017)
Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status
C. Bilir et al.
CURRENT ONCOLOGY (2017)
A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
Hyun Yang et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2017)
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
H. Hagman et al.
ANNALS OF ONCOLOGY (2016)
A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer
Michela Roberto et al.
ANTI-CANCER DRUGS (2016)
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
M. E. Cazzaniga et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients
Teresa Di Desidero et al.
INVESTIGATIONAL NEW DRUGS (2016)
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
Guido Bocci et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Chemotherapy in frail elderly patients with hormone- refractory prostate cancer: A real world experience
Paolo Tralongo et al.
PROSTATE INTERNATIONAL (2016)
Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
Vanita Noronha et al.
SOUTH ASIAN JOURNAL OF CANCER (2016)
Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India
Avinash Pandey et al.
SOUTH ASIAN JOURNAL OF CANCER (2016)
Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience
Avinash Pandey et al.
SOUTH ASIAN JOURNAL OF CANCER (2016)
An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients
Vijay M. Patil et al.
SOUTH ASIAN JOURNAL OF CANCER (2016)
Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
S. B. Dessai et al.
SOUTH ASIAN JOURNAL OF CANCER (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
P. Katsaounis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer
J. Wang et al.
CLINICAL & EXPERIMENTAL METASTASIS (2015)
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer
Giuseppe Cancello et al.
CLINICAL BREAST CANCER (2015)
New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
Joyce M. van Dodewaard-de Jong et al.
CLINICAL GENITOURINARY CANCER (2015)
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience
Roberto Petrioli et al.
CLINICAL LUNG CANCER (2015)
Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure
Alessandro Granito et al.
DIGESTIVE AND LIVER DISEASE (2015)
Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
Dana M. Roque et al.
GYNECOLOGIC ONCOLOGY (2015)
Interferon Alpha and Metronomic Cyclophosphamide for Metastatic Kidney Cancer: A Phase 2 Study
Krzysztof Tupikowski et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2015)
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H. J. Simkens et al.
LANCET (2015)
Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer
Eng Huat Tan et al.
LUNG CANCER (2015)
SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC-3 cells via NF-κB/ERK/Akt signaling pathway
Jin Li et al.
MEDICAL ONCOLOGY (2015)
Continuous, low-dose capecitabine for patients with recurrent colorectal cancer
Adriana Romiti et al.
MEDICAL ONCOLOGY (2015)
Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer A Multicenter Phase 2 Study
Peng Yuan et al.
MEDICINE (2015)
On and off metronomic oral vinorelbine in elderly women with advanced breast cancer
Francesca De Iuliis et al.
TUMORI JOURNAL (2015)
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
Teresa Di Desidero et al.
ONCOTARGET (2015)
Endothelial Progenitor Cells in Tumor Angiogenesis: Another Brick in the Wall
Marina Marcola et al.
STEM CELLS INTERNATIONAL (2015)
On and off metronomic oral vinorelbine in elderly women with advanced breast cancer
Francesca De Iuliis et al.
TUMORI JOURNAL (2015)
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
L. Bazzola et al.
BRITISH JOURNAL OF CANCER (2015)
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
Donna E. Reece et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer
Hiroko Otsuka et al.
BREAST CANCER (2015)
Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
Jong-Yun Woo et al.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY (2015)
Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers
Vijay M. Patil et al.
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY (2015)
A Review of Novel Therapies for Melanoma
Chante Karimkhani et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2014)
A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials
Gemma Cramarossa et al.
BIOMARKERS IN MEDICINE (2014)
Breast Cancer Statistics, 2013
Carol DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Docetaxel Plus Oral Metronomic Cyclophosphamide: A Phase II Study With Pharmacodynamic and Pharmacogenetic Analyses in Castration-Resistant Prostate Cancer Patients
Lisa Derosa et al.
CANCER (2014)
Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Lee S. Schwartzberg et al.
CLINICAL BREAST CANCER (2014)
Metronomic Oral Cyclophosphamide Chemotherapy Possibly Contributes to Stabilization of Disease in Patients With Metastatic Castration-Resistant Prostate Cancer: A Prospective Analysis of Consecutive Cases
Masahiro Yashi et al.
CLINICAL GENITOURINARY CANCER (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer
Yi-Ping Zhu et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2014)
Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure
Fan Zhou et al.
LEUKEMIA & LYMPHOMA (2014)
Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy
Erez Hasnis et al.
NEOPLASIA (2014)
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study
M. E. Cazzaniga et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2014)
Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells
Eddy Pasquier et al.
ANGIOGENESIS (2013)
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
P. Orlandi et al.
BRITISH JOURNAL OF CANCER (2013)
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609
Tetsuya Taguchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Low-dose metronomic chemotherapy: A systematic literature analysis
K. Lien et al.
EUROPEAN JOURNAL OF CANCER (2013)
The efficacy of temozolomide for recurrent glioblastoma multiforme
Chao Chen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
Herman A. Perroud et al.
FUTURE ONCOLOGY (2013)
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
Xenofon Papanikolaou et al.
HAEMATOLOGICA (2013)
Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer
V Noronha et al.
INDIAN JOURNAL OF CANCER (2013)
Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis
P. S. Pai et al.
INDIAN JOURNAL OF CANCER (2013)
Metronomic weekly paclitaxel in advanced unresectable esophageal cancer
V Noronha et al.
INDIAN JOURNAL OF CANCER (2013)
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
James W. Hodge et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
Marta Vives et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Tumour endothelial cells acquire drug resistance in a tumour microenvironment
Kyoko Hida et al.
JOURNAL OF BIOCHEMISTRY (2013)
A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group
Emmanouil Kontopodis et al.
JOURNAL OF CHEMOTHERAPY (2013)
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
Emma L. Barber et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2013)
Has the time come for metronomics in low-income and middle-income countries?
Nicolas Andre et al.
LANCET ONCOLOGY (2013)
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Antonio Omuro et al.
NEURO-ONCOLOGY (2013)
Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
Giovanni Brandi et al.
ONCOLOGIST (2013)
Strange attractors: DAMPs and autophagy link tumor cell death and immunity
W. Hou et al.
CELL DEATH & DISEASE (2013)
Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen
Lu Li et al.
THORACIC CANCER (2013)
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
Giacomo Allegrini et al.
ANGIOGENESIS (2012)
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy
Manuela Miscoria et al.
ANTI-CANCER DRUGS (2012)
Oral Etoposide for Platinum-Resistant and Recurrent Epithelial Ovarian Cancer: a Study by the Anatolian Society of Medical Oncology
Mehmet Kucukoner et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics
Erica L. Mayer et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report
Gaetano Aurilio et al.
BREAST JOURNAL (2012)
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
Zacharenia Saridaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study
Zhonghua Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
Masataka Yoshimoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases
Raffaele Addeo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
Eva Ellebaek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence
David Paez et al.
CLINICAL CANCER RESEARCH (2012)
Can Targeted Therapy be Successful without Metronomic Scheduling ?
Nicolas Andre et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2012)
Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells
Chikara Muraki et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients
Li-Juan Meng et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Regulatory T cell: a protection for tumour cells
Yi Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial
B. Walter et al.
MEDICAL ONCOLOGY (2012)
Capecitabine metronomic chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy
ShengLi He et al.
MEDICAL ONCOLOGY (2012)
Efficacy, Safety, and Biomarkers of Single- Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma
Valerie Boige et al.
ONCOLOGIST (2012)
Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma
Yu-Yun Shao et al.
ONCOLOGY (2012)
Control Dominating Subclones for Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies
Shengwen Calvin Li et al.
STEM CELLS AND DEVELOPMENT (2012)
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
Francesco Legge et al.
BMC CANCER (2011)
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
Silvia Dellapasqua et al.
BREAST (2011)
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
O. A. Khan et al.
BRITISH JOURNAL OF CANCER (2011)
Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer Results of a Phase 2 Study
Kathryn F. McGonigle et al.
CANCER (2011)
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients
Pierpaolo Correale et al.
CANCER BIOLOGY & THERAPY (2011)
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Jitka Fucikova et al.
CANCER RESEARCH (2011)
Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma
Olivier Mir et al.
EUROPEAN JOURNAL OF CANCER (2011)
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
R. Ramasubbaiah et al.
GYNECOLOGIC ONCOLOGY (2011)
Retrospective Analysis of an Oral Combination of Dexamethasone, Uracil plus Tegafur and Cyclophosphamide for Hormone-refractory Prostate Cancer
Koji Hatano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms
Hong Yan et al.
PLOS ONE (2011)
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Antonella Sistigu et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration-refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel
Vittorio Gebbia et al.
UROLOGY (2011)
Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer
Asa Jellvert et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2011)
Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells
Ramon Kaneno et al.
CELLULAR ONCOLOGY (2011)
Metronomic Cyclophosphamide andMethotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
Jorge L. Soriano et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2011)
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
J. J. C. Verhoeff et al.
ANNALS OF ONCOLOGY (2010)
A Phase 2 Pilot Trial of Low-Dose, Continuous Infusion, or Metronomic Paclitaxel and Oral Celecoxib in Patients With Metastatic Melanoma
Rupal S. Bhatt et al.
CANCER (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo
Mohamed L. Salem et al.
CELLULAR IMMUNOLOGY (2010)
Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer
Raffaele Addeo et al.
CLINICAL BREAST CANCER (2010)
Continuous Administration of Low-Dose Cyclophosphamide and Prednisone as a Salvage Treatment for Multiple Myeloma
Fan Zhou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
The growing diversity and spectrum of action of myeloid-derived suppressor cells
Alberto Mantovani
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A. Hurteau et al.
GYNECOLOGIC ONCOLOGY (2010)
Oral metronomic cyclophosphamide in elderly with metastatic melanoma
Estelle Borne et al.
INVESTIGATIONAL NEW DRUGS (2010)
Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate
A. Licchetta et al.
JOURNAL OF CHEMOTHERAPY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
Chih-Hung Hsu et al.
JOURNAL OF HEPATOLOGY (2010)
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
Florian Stockhammer et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER
Andrea Fontana et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2010)
Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
Hop S. Tran Cao et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)
Joaquim Bellmunt et al.
LANCET ONCOLOGY (2010)
Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis
Chi-An Chen et al.
MOLECULAR THERAPY (2010)
Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer
Bernard Lebeau et al.
LUNG CANCER (2010)
Metronomic chemotherapy: new rationale for new directions
Eddy Pasquier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
Doo-Sik Kong et al.
NEURO-ONCOLOGY (2010)
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy
Thomas Nelius et al.
MEDICAL ONCOLOGY (2010)
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
A. Singh et al.
ONCOGENE (2010)
Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
Alfonso Sanchez-Munoz et al.
ONCOLOGY (2010)
Durable complete response of hepatocellular carcinoma after metronomic capecitabine
Giovanni Brandi et al.
TUMORI (2010)
Oral low-dose dexamethasone for androgen-independent prostate cancer patients
Akira Komiya et al.
ONCOLOGY LETTERS (2010)
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Claire Banissi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation
Hiroaki Tanaka et al.
CANCER RESEARCH (2009)
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
Andrea Fontana et al.
CLINICAL CANCER RESEARCH (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Jennifer L. Clarke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
Toru Watanabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: A non-randomized phase II study
V. Surmont et al.
LUNG CANCER (2009)
Continuous Administration of Daily Low-Dose Temozolomide in Pretreated Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study
Charalambos Kouroussis et al.
ONCOLOGY (2009)
被撤回的出版物: Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells (Retracted article. See vol. 119, 2022)
KangAe Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Maximum tolerated dose: clinical endpoint for a bygone era?
Chris H. Takimoto
TARGETED ONCOLOGY (2009)
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
G. Allegrini et al.
BRITISH JOURNAL OF CANCER (2008)
Phase 2 Trial of Temozolomide Using Protracted Low-dose and Whole-brain Radiotherapy for Nonsmall Cell Lung Cancer and Breast Cancer Patients With Brain Metastases
Raffaele Addeo et al.
CANCER (2008)
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma
Levi S. Downs et al.
CANCER (2008)
Cancer chemotherapy:: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
Cedric Menard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
Jose Miguel Jurado Garcia et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Immunogenic cancer cell death: a key-lock paradigm
Antoine Tesniere et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer
J. A. Garcia-Saenz et al.
JOURNAL OF CHEMOTHERAPY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Judah Folkman's Contribution to the Inhibition of Angiogenesis
Diane R. Bielenberg et al.
Lymphatic Research and Biology (2008)
A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
Michael Goern et al.
ONKOLOGIE (2008)
Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Justin C. Chura et al.
GYNECOLOGIC ONCOLOGY (2007)
Models, mechanisms and clinical evidence for cancer dormancy
Julio A. Aguirre-Ghiso
NATURE REVIEWS CANCER (2007)
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer
Peng-Chan Lin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Santosh Kesari et al.
NEURO-ONCOLOGY (2007)
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: A phase II study
R. Lord et al.
JOURNAL OF UROLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients
Peter Laszlo Lakatos et al.
BMC CANCER (2007)
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer
Giuseppe Di Lorenzo et al.
CANCER BIOLOGY & THERAPY (2007)
Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies
Klaus Podar et al.
CELL CYCLE (2007)
Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer
Mary E. Gordinier et al.
JOURNAL OF PALLIATIVE MEDICINE (2007)
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
Aparna A. Kamat et al.
CANCER RESEARCH (2007)
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A hoosier oncology group trial, HEM01-21
Attaya Suvannasankha et al.
ONCOLOGIST (2007)
The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin
JE Damber et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer
Laura Orlando et al.
ANTI-CANCER DRUGS (2006)
Oral etoposide in elderly patients with advanced non small cell lung cancer: A clinical and pharmacological study
R Sorio et al.
JOURNAL OF CHEMOTHERAPY (2006)
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer:: antitumor activity and biological effects
M Colleoni et al.
ANNALS OF ONCOLOGY (2006)
Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid
MFW Gee et al.
ONCOGENE (2005)
A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
K Pietras et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme
J Tuettenberg et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity
VR Rozados et al.
ANNALS OF ONCOLOGY (2004)
Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC)
A Nicolini et al.
BIOMEDICINE & PHARMACOTHERAPY (2004)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
LM Glode et al.
CANCER (2003)
Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma
B Hellerstedt et al.
CANCER (2003)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
M Colleoni et al.
ANNALS OF ONCOLOGY (2002)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
S Ugurel et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer
K Nishimura et al.
ONCOLOGY (2001)
Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer
G Mariani et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
分享论文
